FHTX Foghorn Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FHTX

Price (delayed)

$3.7

Market cap

$217.24M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$168.32M

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 13
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 29

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The ...

Highlights
Foghorn Therapeutics's EPS has increased by 15% YoY
The net income is up by 6% YoY
The equity has grown by 30% from the previous quarter but it has contracted by 24% YoY
FHTX's gross profit is up by 20% year-on-year but it is down by 9% since the previous quarter
The company's debt rose by 20% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://foghorntx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of FHTX

FHTX stock price

How has the Foghorn Therapeutics stock price performed over time
Intraday
1.65%
1 week
-13.35%
1 month
-20.94%
1 year
-11.9%
YTD
-31.48%
QTD
-22.59%

Financial performance

How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$28.22M
Gross profit
$28.22M
Operating income
-$86.68M
Net income
-$75.32M
Gross margin
100%
Net margin
-266.9%
FHTX's operating margin is up by 26% YoY but it is down by 8% QoQ
The company's net margin rose by 22% YoY but it fell by 11% QoQ
FHTX's gross profit is up by 20% year-on-year but it is down by 9% since the previous quarter
The company's revenue rose by 20% YoY but it fell by 9% QoQ

Price vs fundamentals

How does FHTX's price correlate with its fundamentals

Growth

What is Foghorn Therapeutics's growth rate over time

Valuation

What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
9.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.96
Foghorn Therapeutics's EPS has increased by 15% YoY
The equity has grown by 30% from the previous quarter but it has contracted by 24% YoY
FHTX's P/S is 91% lower than its 5-year quarterly average of 100.7 and 25% lower than its last 4 quarters average of 11.9
The company's revenue rose by 20% YoY but it fell by 9% QoQ

Efficiency

How efficient is Foghorn Therapeutics business performance
FHTX's return on invested capital has dropped by 105% year-on-year and by 16% since the previous quarter
The ROA has contracted by 30% YoY and by 6% from the previous quarter
Foghorn Therapeutics's ROS has increased by 22% YoY but it has decreased by 11% from the previous quarter

Dividends

What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FHTX.

Financial health

How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 26% lower than its total liabilities
Foghorn Therapeutics's total assets has decreased by 14% YoY but it has increased by 12% QoQ
The current ratio has contracted by 8% YoY but it has grown by 7% from the previous quarter
The company's debt is 155% higher than its equity
The debt to equity is down by 45% QoQ but it is up by 3.5% YoY
The equity has grown by 30% from the previous quarter but it has contracted by 24% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.